Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CTMX with free AI briefings, catalyst countdowns, and dilution alerts.

CTMX · CytomX Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$348M Cash on Hand
1470.3mo Cash Runway
Follow CTMX by email Get an email when CTMX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CTMX, unsubscribe in one click. Privacy

📣 What CTMX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Pacmilimab (CX-072) Solid Tumor Phase 2 · NCT03993379 Terminated
Praluzatamab Ravtansine (CX-2009) Neoplasms Phase 2 · NCT04596150 Completed
Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029 Solid Tumor, Adult Phase 1/2 · NCT03543813 Completed
Varsetatug Masetecan (CX-2051) Colo-rectal Cancer Phase 1/2 · NCT07900165 Not yet recruiting
PD-1 Directed Probody CX-188 Solid Tumor, Adult Phase 1 · NCT03706274 Withdrawn
Protease-activated Interferon Alpha-2b Prodrug… Solid Tumor, Adult Phase 1 · NCT06462794 Recruiting
Protease-activated Anti-EGFR/Anti-CD3… Solid Tumors Phase 1 · NCT05387265 Terminated

Also used in these trials (approved or third-party drugs, not CTMX's own candidates): Bevacizumab, Ipilimumab, Vemurafenib, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CTMX holds $348M in cash and short-term investments (as of Sep 30, 2026) and burns about $710,000/quarter from operations, an estimated runway of 1470.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 29 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CTMX files for a raise →

👥 Who Owns CTMX

Insiders 1% Other 5%+ holders 7% Institutions (251 holders) 92% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 24,688,109 11.32% 2025-12-31
BlackRock, Inc. Institution (13G, 5%+) 16,551,452 7.59% 2026-06-30
Patrick G. Enright 5%+ holder (13G) 15,288,461 7.01% 2026-03-31
BANK OF AMERICA CORP /DE/ Institution (13G, 5%+) 11,867,012 5.44% 2026-09-30
Sean A. McCarthy
CEO, Director · +2.18M options
Insider 1,172,080 0.54% 2026-03-17
Marcia Belvin
SVP, Chief Scientific Officer · +304,450 options
Insider 300,760 0.14% 2026-03-17
Christopher Ogden
Chief Financial Officer · +442,400 options
Insider 295,324 0.14% 2026-06-15
Yu-Waye Chu
Chief Medical Officer · +431,250 options
Insider 189,446 0.09% 2026-03-17
Alejandra Carvajal
Chief Legal Officer · +450,000 options
Insider 100,000 0.05% 2026-08-03
Rachael Lester
Chief Business Officer · +750,000 options
Insider 20,000 0.01% 2026-02-02

Share count 218,004,920 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CTMX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CTMX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.